Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Stroke
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Stroke
    Antithrombotic Medication Use Not Improving Among Ischaemic Stroke Survivors - (DGNews)
    High Salt Intake Linked to Strokes, Cardiovascular Disease - (DGNews)
    TopAbstracts in Stroke 11/26/2009 - (DGNews)
    Obesity Leading Risk Factor of Left Atrial Enlargement During Aging - (DGNews)
    Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies - (BMJ)

    News archive

     Recent webcasts/CME - Stroke
    • The Evolving Role of Antiplatelet Therapy for Atrial Fibrillation: Highlights From the ACC Scientific Sessions 2009
    • Current Standard of Care for Stroke Prevention in Patients With Atrial Fibrillation (AF)
    • Aneurysm Rupture and Subarachnoid Hemorrhage Cerebral Revascularization: The Role of EC-IC Bypass in the 21st Century
      Stenting for Intracranial Atherosclerosis
      Diffusion-Weighted Imaging: Not All That Glitters Is Gold

      Webcasts/CME archive

       Recent cases - Stroke
        Adult Cor Triatriatum Presenting as Cardioembolic Stroke
        Pure Sensory Stroke Form Compression of Putaminal Hemorrhage: A Case Report
        An Echocardiographic-Confirmed Case of Atrial Myxoma Causing Cerebral Embolic Ischemic Stroke: A Case Report
        Diffusion-Negative MRI in Acute Ischemic Stroke: A Case Report
        F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for the Diagnosis of Takayasu's Arteritis in Stroke: A Case Report

        Cases archive
          




        my personal edition > stroke > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pioglitazone Reduces Risk of Second Stroke in Diabetic Patients; No Impact Seen on Risk of First Ever Events: Presented at WCC

        By Cameron Johnston

        BARCELONA, SPAIN -- September 6, 2006 -- Patients with type 2 diabetes who have experienced a stroke may have a significantly reduced risk of subsequent strokes when their diabetes is treated with the peroxisome proliferator-activated receptor (PPAR)-agonist pioglitazone, according to research presented here at the European Society of Cardiology World Congress of Cardiology (WCC).

        The same study also showed, however, that the results did not carry over to patients who had never had a stroke. For unknown reasons, pioglitazone did not appear to prevent the first ever strokes among these patients, the researchers said in a presentation on September 3rd.

        Discussing the results of the study, Robert Wilcox, MD, professor of cardiovascular medicine, Queen's Medical Centre, Nottingham, United Kingdom, pointed out that while blood pressure and lipid control are 2 of the most successful strategies for preventing stroke in the general population, no studies have ever demonstrated a benefit to glucose-lowering therapies among patients with type 2 diabetes.

        The present study involved more than 5,200 patients with type 2 diabetes and macrovascular disease in 19 sites across Europe. Of the original cohort, 984 had history of stroke (ie, more than 6 months prior to enrollment in the trial), while 4254 had never had any form of stroke. Of those who had had a prior stroke, 486 were treated with pioglitazone as well as the usual diet and drug regimens to treat their diabetes, while 498 received a placebo in addition to their usual diabetic therapy.

        Patients were followed for a median of 2.85 years. The primary endpoints of the study were all-cause mortality, nonfatal strokes, acute coronary syndrome, and/or myocardial infarction (MI).

        While patients were more or less matched for demographic factors, those with no history of prior stroke were more likely to have had coronary artery bypass surgery, a prior MI, peripheral artery disease, or acute coronary syndrome compared with patients who had had a prior stroke.

        As far as laboratory parameters go, there were significant improvements in hemoglobin A1c, serum triglycerides, and high-density lipoprotein among patients who had already had a stroke and were taking pioglitazone compared with those who had had a prior stroke but were receiving a placebo.

        There were clear differences (P = .008) in time to fatal or nonfatal strokes between the 2 groups, with 27 of 486 who received pioglitazone having an event within 3 years of enrollment compared with 51 of 498 who received placebo.

        Among patients who had not had a prior event, there were no differences in time to first event regardless of whether they were taking a placebo or pioglitazone.

        Overall, there were numerical differences in the numbers of patients who achieved the primary endpoints and main secondary endpoints, as well as those who had fatal or nonfatal stroke or fatal or nonfatal MI, but in no case were these differences statistically significant, Dr. Wilcox reported.

        In fact, of the entire cohort of more than 5,200 patients, prior stroke was the strongest predictor of a second event, and pioglitazone or statin use were shown to be the only factors that reduced this risk.

        Age, poor glucose control, kidney disease, and peripheral artery disease were the strongest predictors of stroke among those who had never experienced a cerebrovascular event.

        In conclusion, Dr. Wilcox said it remains to be seen whether pioglitazone use would show a benefit in terms of reducing the risk of first stroke among patients who had never had a stroke if treatment was continued long enough. Another question is whether pioglitazone use would reduce the risk of stroke among nondiabetic patients at high risk of macrovascular disease.


        [Presentation title: Effect of Pioglitazone in Stroke Prevention in Type 2 Diabetes: a Prespecified Subgroup Analysis of PROactive. Abstract 120]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send